- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05983861
Risk Factors for Multidrug Resistant Bacteria at ICU Admission
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Infection is one of the main reason for a patient to be admitted to an intensive care unit (ICU) and it's fundamental to use the right antibiotic as soon as possible, possibly needing broad-spectrum antibiotics. However, the main problem is that widening the spectrum of drugs will generate pressure on the hospital microbiota, leading to the development of multi-drug resistant bacteria
Purpose: A large number of ICU-admitted patients have infection/sepsis as their major problem, requiring treatment with antibiotics. With knowledge of the presumed risk factors for antibiotic resistance, the assistant physician could use broad-spectrum drugs with greater certainty.
Objectives: Our objective will be to evaluate risk factors for infection caused by multi-drug resistant germs upon ICU admission and assess the severity of the disease in comparison to patients infected with susceptible bacteria. Ultimately, we aim to develop and validate a clinical tool to assist physicians in selecting the appropriate antibiotic for their patients
Methods: An observational prospective study with a control group will be conducted, including all patients admitted to the ICU with an infectious disease initiated within 48 hours of hospital admission and with a positive microbiologic result. Patients with isolation of only susceptible bacteria will be allocated to the control group, while patients with MDR bacteria will be assigned to the study group, referred to as the MDR group. The data to be collected will include sex, age, previous use of antibiotics in the last three months, previous hospital admissions, previous isolation of MDR germs, sensitivity profile of the isolated germs, severity of disease (measured by SAPS 3), presence of sepsis diagnosis at admission, length of stay in the ICU, and 28-day mortality
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: PAULO BEZERRA, MD
- Phone Number: +55 98988748865
- Email: drpaulobezerra@gmail.com
Study Contact Backup
- Name: PEDRO FROTA, MD
- Phone Number: +55 98999769456
- Email: pedrohfrota@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients admitted to the ICU with an infectious disease initiated within 48 hours of hospital admission and a microbiological positive result for bacteria
Exclusion Criteria:
- Patients with results considered as contamination according to the institutional protocol.
- Surgical wound and bloodstream infections.
- Microbiological isolation of only fungi.
- Vigilance cultures, such as anal, rectal, nasal, and axillary swabs.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Multi drug resistant group
All critically ill adult patients (with no exclusion criteria) admitted to the ICU with microbiological confirmed diagnosis of infection at admission and multi drug resistant bacteria isolation :
|
Identification o Multi Drug Resistant Bacteria
|
Multi sensible bacteria group
All critically ill adult patients (with no exclusion criteria) admitted to the ICU with microbiological confirmed diagnosis of infection at admission and multi drug sensible bacteria isolation :
|
Identification o Multi Drug Resistant Bacteria
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine risk factors for multi-drug resistant germs in ICU admission.
Time Frame: 28 days
|
Analysis of resistance profile of germs and patient's comorbidities to determine the risk factors for drug resistance.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality between control and case group
Time Frame: 28 days
|
Compare mortality in 28 days between patients with infection caused by MDR bacteria and non-resistant bacteria.
|
28 days
|
Mean LOS of each group
Time Frame: 28 days
|
Compare the length of stay in ICU between the control and case groups.
|
28 days
|
Severity between groups using SAPS 3
Time Frame: 28 days
|
Compare the severity of disease between groups using the SAPS 3 score.
|
28 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Hylander Moller M, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 Nov 1;49(11):e1063-e1143. doi: 10.1097/CCM.0000000000005337. No abstract available.
- Niederman MS, Baron RM, Bouadma L, Calandra T, Daneman N, DeWaele J, Kollef MH, Lipman J, Nair GB. Initial antimicrobial management of sepsis. Crit Care. 2021 Aug 26;25(1):307. doi: 10.1186/s13054-021-03736-w.
- Bassetti M, Rello J, Blasi F, Goossens H, Sotgiu G, Tavoschi L, Zasowski EJ, Arber MR, McCool R, Patterson JV, Longshaw CM, Lopes S, Manissero D, Nguyen ST, Tone K, Aliberti S. Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. Int J Antimicrob Agents. 2020 Dec;56(6):106184. doi: 10.1016/j.ijantimicag.2020.106184. Epub 2020 Oct 9.
- Kalil AC, Johnson DW, Lisco SJ, Sun J. Early Goal-Directed Therapy for Sepsis: A Novel Solution for Discordant Survival Outcomes in Clinical Trials. Crit Care Med. 2017 Apr;45(4):607-614. doi: 10.1097/CCM.0000000000002235.
- Liu VX, Fielding-Singh V, Greene JD, Baker JM, Iwashyna TJ, Bhattacharya J, Escobar GJ. The Timing of Early Antibiotics and Hospital Mortality in Sepsis. Am J Respir Crit Care Med. 2017 Oct 1;196(7):856-863. doi: 10.1164/rccm.201609-1848OC.
- Wong D, Wong T, Romney M, Leung V. Comparative effectiveness of beta-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Ann Clin Microbiol Antimicrob. 2016 Apr 26;15:27. doi: 10.1186/s12941-016-0143-3.
- Fernandez-Martinez NF, Carcel-Fernandez S, De la Fuente-Martos C, Ruiz-Montero R, Guzman-Herrador BR, Leon-Lopez R, Gomez FJ, Guzman-Puche J, Martinez-Martinez L, Salcedo-Leal I. Risk Factors for Multidrug-Resistant Gram-Negative Bacteria Carriage upon Admission to the Intensive Care Unit. Int J Environ Res Public Health. 2022 Jan 18;19(3):1039. doi: 10.3390/ijerph19031039.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 17/2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multi Drug Resistant Bacteria
-
Centre Hospitalier Régional Metz-ThionvilleCompletedMulti-drug Resistant BacteriaFrance
-
Association Pour le Recherche en Infectiologie...Pr Bruno FantinCompletedColonization | Hospitalized Patients | Multi Drug Resistant BacteriaFrance
-
Emory UniversityCenters for Disease Control and PreventionNot yet recruitingMulti-Drug Resistant Organism ColonizationUnited States
-
Emory UniversityCenters for Disease Control and PreventionRecruitingMulti-drug Resistant OrganismUnited States
-
Emory UniversityCenters for Disease Control and PreventionCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
EpicentreMedecins Sans Frontieres, NetherlandsCompletedTuberculosis | Multi Drug Resistant TuberculosisUganda
-
Assistance Publique - Hôpitaux de ParisRecruitingMulti-Drug Resistant TuberculosisFrance
-
Janssen Research & Development, LLCCompletedPulmonary Multi-drug Resistant TuberculosisUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAdults Patients, With Fecal Carriage of Multi-Drug Resistant Enterobacterales (MDR-E)
Clinical Trials on Identification o Multi Drug Resistant Bacteria
-
Hopital LariboisièreCompletedBeta Lactam Resistant Bacterial Infection (Disorder)France
-
Janssen Infectious Diseases BVBACompletedTuberculosisSouth Africa, Peru, Latvia, Philippines, Russian Federation, Thailand, Brazil, India
-
Manhattan Beach OrthodonticsNot yet recruitingMigraineUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityTerminatedPrimary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditionsUnited States